Cardiovascular risks of antiretroviral therapies.

Cardiovascular risks of antiretroviral therapies. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cardiovascular risks of antiretroviral therapies. Abstract Text:

Kristin Mondy,Pablo Tebas,

The use of highly active antiretroviral therapy (HAART) has resulted in sustained reductions in mortality from HIV infection. In recent years, HAART has also been associated with metabolic complications that may increase patients' cardiovascular disease risk. Recent studies have begun to support a more complex interaction between HAART, HIV infection itself, and other traditional social and immunologic factors that may predispose patients to premature cardiovascular disease. Substantial progress has been made in the development of newer antiretroviral therapies that have a better metabolic profile with respect to dyslipidemia, hyperglycemia, and lipodystrophy. Optimal selection of metabolically neutral antiretroviral therapies, together with aggressive management of other modifiable coronary risk factors, may improve cardiovascular disease risk in the long term.

Cardiovascular risks of antiretroviral therapies. Publishing Authors By Initials

K Mondy,P Tebas,

For similar biochemical phenomena, metabolism, and nutrition: metabolism: lipid metabolism research abstracts see: biochemical phenomena, metabolism, and nutrition: metabolism: lipid metabolism research

PUBMED ID PMID:

MEDLINE DATE:

Cardiovascular risks of antiretroviral therapies. Journal Published:

PUBLICATION TYPE: Review

Journal: Annual review of medicine

VOLUME: 58

Page Numbers: 141-55

Journal Abbreviation: Annu. Rev. Med.

ISSN: 0066-4219

DAY: 3

MONTH: 12

YEAR: 2007

Cardiovascular risks of antiretroviral therapies. Information

Number of References: 63

LANGUAGE: eng

NlmUniqueID: 2985151

Cardiovascular risks of antiretroviral therapies. Keywords Mesh Terms:

KEYWORDS: Lipid Metabolism

MESH TERMS: drug effects

Chemical & Substance for Abstract: Cardiovascular risks of antiretroviral therapies. Information

Substance Name: Blood Glucose

Registry Number: 0

Grant and Affiliation Information for Cardiovascular risks of antiretroviral therapies.

AFFILIATION: Washington University School of Medicine, Saint Louis, Missouri 63110, USA. kmondy@im.wustl.edu

Country: United States

AGENCY: United States NIAID

GRANT: K23 AI06533601

ACRONYM: AI

MEDLINETA: Annu Rev Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cardiovascular risks of antiretroviral therapies Related Publications

• Cardiovascular risks of antiretroviral therapies.
• Interventions for body habitus changes associated with HIV infection and its treatment.